BR112020002271A2 - conjugados de citocina para o tratamento de doenças proliferativas e infecciosas - Google Patents

conjugados de citocina para o tratamento de doenças proliferativas e infecciosas Download PDF

Info

Publication number
BR112020002271A2
BR112020002271A2 BR112020002271-3A BR112020002271A BR112020002271A2 BR 112020002271 A2 BR112020002271 A2 BR 112020002271A2 BR 112020002271 A BR112020002271 A BR 112020002271A BR 112020002271 A2 BR112020002271 A2 BR 112020002271A2
Authority
BR
Brazil
Prior art keywords
polypeptide
cell
modified
cases
amino acid
Prior art date
Application number
BR112020002271-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Jerod Ptacin
Carolina E. CAFFARO
Marcos MILLA
Original Assignee
Synthorx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthorx, Inc. filed Critical Synthorx, Inc.
Publication of BR112020002271A2 publication Critical patent/BR112020002271A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
BR112020002271-3A 2017-08-03 2018-08-03 conjugados de citocina para o tratamento de doenças proliferativas e infecciosas BR112020002271A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540781P 2017-08-03 2017-08-03
US62/540,781 2017-08-03
PCT/US2018/045257 WO2019028419A1 (en) 2017-08-03 2018-08-03 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES

Publications (1)

Publication Number Publication Date
BR112020002271A2 true BR112020002271A2 (pt) 2020-07-28

Family

ID=65234189

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112020002271-3A BR112020002271A2 (pt) 2017-08-03 2018-08-03 conjugados de citocina para o tratamento de doenças proliferativas e infecciosas
BR112020002272-1A BR112020002272A2 (pt) 2017-08-03 2018-08-03 conjugados de citocina para o tratamento de doenças autoimunes

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112020002272-1A BR112020002272A2 (pt) 2017-08-03 2018-08-03 conjugados de citocina para o tratamento de doenças autoimunes

Country Status (19)

Country Link
US (8) US11622993B2 (https=)
EP (2) EP3661955A4 (https=)
JP (5) JP7654401B2 (https=)
KR (6) KR102708105B1 (https=)
CN (2) CN111183149A (https=)
AR (1) AR112969A1 (https=)
AU (6) AU2018309172B2 (https=)
BR (2) BR112020002271A2 (https=)
CA (2) CA3071013A1 (https=)
CO (2) CO2020001823A2 (https=)
IL (4) IL322312A (https=)
MA (2) MA49767A (https=)
MX (4) MX2020001332A (https=)
MY (1) MY200827A (https=)
PH (2) PH12020500241A1 (https=)
SA (2) SA520411204B1 (https=)
SG (2) SG11202000944SA (https=)
TW (2) TWI906467B (https=)
WO (2) WO2019028419A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250099355A1 (en) * 2023-07-18 2025-03-27 Sytheon Ltd Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN111527109B (zh) * 2017-12-26 2024-11-01 南京金斯瑞生物科技有限公司 以抗体Fc区为骨架的融合蛋白二聚体及其应用
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CA3091857A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
HRP20240016T1 (hr) * 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020057646A1 (zh) 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
EP3854805A4 (en) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
GB201817444D0 (en) * 2018-10-26 2018-12-12 Res & Innovation Uk Methods and compositions
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
KR20220004134A (ko) * 2019-04-26 2022-01-11 프로린크스 엘엘시 서방형 사이토카인 컨쥬게이트
US20220241375A1 (en) 2019-05-20 2022-08-04 Cytune Pharma Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
EP3986917A1 (en) * 2019-06-20 2022-04-27 CSPC Megalith Biopharmaceutical Co., Ltd. Modified il-2 proteins, peg conjugates, and uses thereof
CN114555128A (zh) * 2019-08-15 2022-05-27 新索思股份有限公司 采用il-2缀合物的免疫肿瘤学组合疗法
EP4013777A4 (en) * 2019-08-15 2024-01-17 Cytimm Therapeutics, Inc. MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
CN114555632A (zh) 2019-08-23 2022-05-27 新索思股份有限公司 Il-15缀合物及其用途
CN114853874B (zh) * 2019-09-10 2024-05-17 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
CA3153644A1 (en) 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
IL291786A (en) 2019-11-04 2022-06-01 Synthorx Inc Interleukin 10 conjugates and their use
EP3819307A1 (en) 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
CN114478743A (zh) * 2019-12-17 2022-05-13 北京志道生物科技有限公司 白介素-2衍生物
KR20220118473A (ko) 2019-12-23 2022-08-25 신톡스, 인크. N6-((2-아지도에톡시)카르보닐)라이신의 제조 방법
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
CA3166420A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Il2 orthologs and methods of use
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
TWI839476B (zh) * 2020-02-26 2024-04-21 大陸商北京泰德製藥股份有限公司 介白素-2多肽共軛物及其用途
WO2021183832A1 (en) * 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AR121891A1 (es) * 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
US12351850B2 (en) 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
EP4146794A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
MX2022014082A (es) 2020-06-03 2022-12-07 Ascendis Pharma Oncology Div A/S Secuencias de interleucina (il-2) y usos de las mismas.
US20210393743A1 (en) * 2020-06-21 2021-12-23 Ketan Desai Use of IL13 for prevention and treatment of COVID19
JP2023531509A (ja) * 2020-06-25 2023-07-24 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
KR102846963B1 (ko) 2020-08-05 2025-08-18 신테카인, 인크. IL27Rα 결합 분자 및 사용 방법
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
JP7743500B2 (ja) 2020-08-05 2025-09-24 シンセカイン インコーポレイテッド Ｉｌ１０受容体結合性分子および使用方法
US20240026014A1 (en) 2020-08-05 2024-01-25 Synthekine, Inc. Compositions and methods related to receptor pairings
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
KR20230061394A (ko) 2020-08-05 2023-05-08 신테카인, 인크. IL10Ra 결합 분자 및 사용 방법
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
US20230272094A1 (en) 2020-08-05 2023-08-31 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
JP7819178B2 (ja) 2020-08-05 2026-02-24 シンセカイン インコーポレイテッド ＩＬ１０Ｒｂ結合分子および使用方法
US12421286B2 (en) 2020-09-04 2025-09-23 Shandong Simcere Biopharmaceutical Co., Ltd. Il-2 mutant and application thereof
CA3192331A1 (en) 2020-09-14 2022-03-17 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076859A1 (en) 2020-10-09 2022-04-14 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
AU2021356693A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
CN116615247A (zh) * 2020-10-09 2023-08-18 新索思股份有限公司 用il-2缀合物和派姆单抗的免疫肿瘤学组合疗法
CN116635061A (zh) * 2020-10-09 2023-08-22 新索思股份有限公司 用il-2缀合物的免疫肿瘤学疗法
CA3195612A1 (en) * 2020-10-14 2022-04-21 Haining HUANG Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
MX2023004880A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
CN112279906B (zh) * 2020-10-30 2022-09-20 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其制备方法与应用
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
TW202242085A (zh) 2020-12-31 2022-11-01 美商艾歐凡斯生物治療公司 供自動生產腫瘤浸潤淋巴球的裝置和方法
WO2022150788A2 (en) 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to receptor pairing
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
WO2022187741A2 (en) 2021-03-05 2022-09-09 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
WO2022198141A1 (en) 2021-03-19 2022-09-22 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
CN116854802A (zh) * 2021-04-13 2023-10-10 苏州复融生物技术有限公司 白介素2突变体及其应用
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2022245754A1 (en) 2021-05-17 2022-11-24 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
WO2022260916A1 (en) * 2021-06-08 2022-12-15 Merck Sharp & Dohme Llc Functional cell-based potency assay for measuring biological activity of interleukin 2 (il-2) analogs
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
US20250002601A1 (en) 2021-06-09 2025-01-02 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
WO2023281485A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20230181754A1 (en) * 2021-07-09 2023-06-15 Bright Peak Therapeutics Ag Modified checkpoint inhibitors and uses thereof
WO2023281479A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
US20230201364A1 (en) * 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230201365A1 (en) * 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
CA3226163A1 (en) 2021-07-14 2023-01-19 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
US20240365776A1 (en) 2021-07-22 2024-11-07 Iovance Biotherapeutics, Inc Method for cryopreservation of solid tumor fragments
US20240342285A1 (en) 2021-07-28 2024-10-17 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
WO2023005680A1 (zh) * 2021-07-30 2023-02-02 西安龙腾景云生物科技有限公司 一种人白细胞介素2变体及其用途
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN113698468B (zh) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其应用
CN113788890B (zh) * 2021-09-01 2022-11-08 浙江新码生物医药有限公司 一种人白细胞介素2-聚乙二醇偶联物及其应用
IL311333A (en) 2021-09-09 2024-05-01 Iovance Biotherapeutics Inc Processes for generating til products using pd-1 talen knockdown
EP4404969A1 (en) 2021-09-24 2024-07-31 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
WO2023064802A1 (en) 2021-10-13 2023-04-20 The Trustees Of Columbia University In The City Of New York Methods for controlling osteocalcin release
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4430076A2 (en) * 2021-11-08 2024-09-18 Life Technologies AS Polymer-interaction molecule conjugates and methods of use
EP4430167A1 (en) 2021-11-10 2024-09-18 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250302950A1 (en) 2021-12-20 2025-10-02 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
CN114349843B (zh) * 2022-01-18 2024-05-14 浙江博锐生物制药有限公司 白细胞介素-2衍生物及其制备方法和应用
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CN114533730B (zh) * 2022-02-17 2024-06-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） Triapine用于治疗非洲猪瘟病毒感染的应用
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4504220A1 (en) 2022-04-06 2025-02-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
CN116036243B (zh) * 2022-04-20 2026-03-24 北京大学宁波海洋药物研究院 受体偏向的peg化il-2变体组合及其应用
EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
CN114767835A (zh) * 2022-05-18 2022-07-22 北京键凯科技股份有限公司 一种治疗结直肠癌的药物组合物及其应用
WO2023235790A1 (en) * 2022-06-01 2023-12-07 University Of Miami Bifunctional il-2 and il-10 fusion proteins and uses thereof
CN119365482A (zh) * 2022-06-17 2025-01-24 舒泰神（北京）生物制药股份有限公司 白介素-2(il-2)突变体及其用途
US20260008990A1 (en) 2022-07-06 2026-01-08 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
EP4583889A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
CN118056840A (zh) * 2022-11-18 2024-05-21 南京诺艾新生物技术有限公司 受体亲和力偏好性的定点偶联聚乙二醇化白介素-2突变体及其用途
EP4623072A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
CN121002050A (zh) 2023-02-21 2025-11-21 艾诺康医药公司 编码经修饰的白细胞介素2（il2）多肽的多核苷酸以及其制备和使用方法
TW202444349A (zh) 2023-03-20 2024-11-16 美商欣爍克斯公司 使用ｉｌ－２綴合物之癌症療法
WO2024211306A1 (en) 2023-04-03 2024-10-10 Sutro Biopharma, Inc. Rf1 ko e. coli strains
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
AU2024296516A1 (en) 2023-07-13 2026-01-22 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
AU2024292473A1 (en) 2023-07-19 2026-01-29 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
WO2026055280A1 (en) 2024-09-04 2026-03-12 Sanofi Interleukin 2 (il-2) and cd123 nk cell engager combination therapy
WO2026072794A2 (en) 2024-09-26 2026-04-02 Iovance Biotherapeutics, Inc. Expansion processes for til product enriched with neoantigen- reactive t cells (narts)

Family Cites Families (331)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5015733A (en) 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5656493A (en) 1985-03-28 1997-08-12 The Perkin-Elmer Corporation System for automated performance of the polymerase chain reaction
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS61225199A (ja) * 1985-03-29 1986-10-06 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−ロイキン２ポリペチド誘導体
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5093232A (en) 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (ja) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
WO1989009221A1 (en) 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
ATE142272T1 (de) 1989-01-19 1996-09-15 Behringwerke Ag Nukleinsäure-amplifikation unter verwendung eines einzelprimers
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
ATE269870T1 (de) 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
WO1991014781A1 (en) 1990-03-19 1991-10-03 Henkel Research Corporation METHOD FOR INCREASING THE OMEGA-HYDROXYLASE ACTIVITY IN $i(CANDIDA TROPICALIS)
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
JPH04126084A (ja) 1990-05-11 1992-04-27 Hoechst Japan Ltd 蛋白質の製造法
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
ES2083593T3 (es) 1990-08-03 1996-04-16 Sterling Winthrop Inc Compuestos y metodos para inhibir la expresion de genes.
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
CA2092002A1 (en) 1990-09-20 1992-03-21 Mark Matteucci Modified internucleoside linkages
NZ239893A (en) 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO1992008728A1 (en) 1990-11-08 1992-05-29 Hybridon, Inc. Incorporation of multiple reporter groups on synthetic oligonucleotides
US5268273A (en) 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5389529A (en) 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5612199A (en) 1991-10-11 1997-03-18 Behringwerke Ag Method for producing a polynucleotide for use in single primer amplification
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
DE9115660U1 (de) 1991-12-18 1992-07-30 Aventis Research & Technologies GmbH & Co KG, 65929 Frankfurt L-Phenylalanyl-tRNA-Synthetase mit erweiterter Substratselektivität aus Mikroorganismen
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
TW263437B (https=) 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
US6288302B1 (en) 1992-11-04 2001-09-11 National Science Council Of R.O.C. Application of α-amylase gene promoter and signal sequence in the production of recombinant proteins in transgenic plants and transgenic plant seeds
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
AU6449394A (en) 1993-03-30 1994-10-24 Sterling Winthrop Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
JPH08508490A (ja) 1993-03-31 1996-09-10 スターリング ウィンスロップ インコーポレイティド 新規５’−置換ヌクレオシド及びそれから得られるオリゴマー
CA2159629A1 (en) 1993-03-31 1994-10-13 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US6294323B1 (en) 1993-04-14 2001-09-25 Behringwerke Ag Self initiating single primer amplification of nucleic acids
GB9311682D0 (en) 1993-06-05 1993-07-21 Ciba Geigy Ag Chemical compounds
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5470719A (en) 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
JPH0889278A (ja) 1994-09-29 1996-04-09 Ajinomoto Co Inc 遺伝子導入用修飾蛋白質及びその製法
US5712114A (en) 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
US6143557A (en) 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
DK0937098T3 (da) 1995-06-07 2002-12-02 Invitrogen Corp Rekombinatorisk kloning under anvendelse af gensplejsede rekombinationssites
US6261797B1 (en) 1996-01-29 2001-07-17 Stratagene Primer-mediated polynucleotide synthesis and manipulation techniques
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
JPH09324000A (ja) 1996-06-05 1997-12-16 Suntory Ltd インターロイキン−２受容体を特異的に認識する因子とリボヌクレアーゼとの接合体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US6054271A (en) 1997-10-21 2000-04-25 The Regents Of The University Of California Methods of using synthetic molecules and target sequences
AU1113999A (en) 1997-10-21 1999-05-10 Regents Of The University Of California, The Target sequences for synthetic molecules and methods of using same
US5932474A (en) 1997-10-21 1999-08-03 The Regents Of The University Of California Target sequences for synthetic molecules
US6008378A (en) 1997-10-21 1999-12-28 The Regents Of The University Of California Synthetic molecules that specifically react with target sequences
EP1025217B1 (en) 1997-10-24 2006-10-04 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
DE19813317A1 (de) 1998-03-26 1999-09-30 Roche Diagnostics Gmbh Verbessertes Verfahren zur Primer Extension Präamplifikations-PCR
US6391544B1 (en) 1998-05-15 2002-05-21 Abbott Laboratories Method for using unequal primer concentrations for generating nucleic acid amplification products
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
AU5300299A (en) 1998-08-21 2000-03-14 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
EP2119788A1 (en) 1999-03-02 2009-11-18 Life Technologies Corporation Compositions and methods for use in recombinational cloning of nucleic acids
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU5088600A (en) 1999-06-03 2000-12-28 Bioinnovation Limited Gene therapy products
EP1114827B1 (en) 1999-07-15 2010-11-17 Japan Science and Technology Agency Novel nucleic acid base pair
JP4949585B2 (ja) 1999-10-29 2012-06-13 アジレント・テクノロジーズ・インク Ｄｎａポリメラーゼを使用した組成物および方法
EP2210948A3 (en) 1999-12-10 2010-10-06 Life Technologies Corporation Use of multiple recombination sites with unique specificity in recombinational cloning
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20020001804A1 (en) 2000-02-25 2002-01-03 Wayne Mitchell Genomic analysis of tRNA gene sets
WO2002036626A1 (en) 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
US20040122223A1 (en) 2001-02-07 2004-06-24 Davis Jeremy Martin Non-natural nucleotides and dinucleotides
US20020170681A1 (en) 2001-02-23 2002-11-21 Alain Saurer Letter moistener
RU2003129164A (ru) 2001-03-01 2005-03-20 Фармассет Лтд. (Bb) Способ синтеза 2`,3`-дидезокси-2`,3`-дидегидронуклеозидов
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
AUPR975201A0 (en) 2001-12-24 2002-01-24 Unisearch Limited Enzymatic redox labelling of nucleic acids
US20060074035A1 (en) 2002-04-17 2006-04-06 Zhi Hong Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections
EP1544294B8 (en) 2002-07-17 2014-03-19 Riken Nucleosides or nucleotides having novel unnatural bases and use thereof
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2507189C (en) 2002-11-27 2018-06-12 Sequenom, Inc. Fragmentation-based methods and systems for sequence variation detection and discovery
NZ541122A (en) 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004094593A2 (en) 2003-04-17 2004-11-04 The Scripps Research Institute Expanding the eukaryotic genetic code
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
JP4956802B2 (ja) 2003-09-10 2012-06-20 独立行政法人理化学研究所 非天然型塩基を有するヌクレオシド又はヌクレオチド及びその利用
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
US7348146B2 (en) 2003-10-02 2008-03-25 Epoch Biosciences, Inc. Single nucleotide polymorphism analysis of highly polymorphic target sequences
EP2145956B1 (en) 2003-11-03 2015-06-17 Medical Research Council Polymerase
EP2327724A3 (en) * 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
BRPI0508470A (pt) 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
TWI417303B (zh) 2004-03-11 2013-12-01 Fresenius Kabi De Gmbh 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
US20060084136A1 (en) 2004-07-14 2006-04-20 Invitrogen Corporation Production of fusion proteins by cell-free protein synthesis
AU2005328382C1 (en) 2004-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
JPWO2006049297A1 (ja) 2004-11-08 2008-05-29 独立行政法人理化学研究所 新規なヌクレオシド若しくはヌクレオチド誘導体及びその利用
AU2006207987B2 (en) 2005-01-27 2011-09-15 Novartis Vaccines And Diagnostics Inc. Methods for treating renal cell carcinoma
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
JP5649018B2 (ja) 2005-08-04 2015-01-07 タグシクス・バイオ株式会社 新規人工塩基対及びその利用
JP5146957B2 (ja) 2005-12-09 2013-02-20 独立行政法人理化学研究所 核酸の複製の方法及び新規人工塩基対
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
DK1984382T3 (da) 2006-01-27 2012-09-03 Santaris Pharma As LNA modificerede fosforthiolerede oligonukleotider
WO2007093599A1 (en) 2006-02-14 2007-08-23 Basf Se Pyridin-4 -ylmethylamides for combating pests
AU2007219793A1 (en) 2006-02-22 2007-09-07 Riken Method for synthesis of suppressor tRNA, DNA construct, and production of protein having non-natural amino acid integrated therein by using the DNA construct
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
EP2444499A3 (en) 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
EP2064333B1 (en) 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
JP5603074B2 (ja) 2006-09-08 2014-10-08 ピラマル イメージング ソシエテ アノニム １８ｆ標識物質のための化合物と方法
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
WO2008067825A1 (en) 2006-12-06 2008-06-12 Erik Bjerregaard Pedersen Hoogsteen-type triplex formation of pyrene labelled probes for nucleic acid detection in fluorescence assay
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
WO2008111485A1 (ja) 2007-03-09 2008-09-18 Riken モノヌクレオシドまたはモノヌクレオチドから誘導される構造を有する化合物、核酸、標識物質、核酸検出方法およびキット
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
JP5679147B2 (ja) 2008-02-07 2015-03-04 独立行政法人理化学研究所 非天然塩基を含む改変ｔＲＮＡ及びその用途
AU2009232716B2 (en) 2008-03-31 2015-02-05 Tagcyx Biotechnologies Novel DNA capable of being amplified by PCR with high selectivity and high efficiency
EP2336332A3 (en) 2008-04-29 2011-11-09 Monsanto Technology LLC Genes and uses for plant enhancement
US20100112660A1 (en) 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
WO2010023670A2 (en) 2008-08-28 2010-03-04 Insight Biopharmaceuticals Ltd. Methods for covalently attaching a polymer to a methionine residue in proteins and peptides
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
CN102307905B (zh) 2008-12-10 2015-11-25 斯克利普斯研究院 利用化学反应性非天然氨基酸产生载体-肽偶联物
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
EP2487181A4 (en) 2009-10-06 2013-08-28 Riken ARTIFICIAL BASIC COUPLE FOR THE FORMATION OF SPECIFIC BASIC COUPLES
EP2495258B1 (en) 2009-10-29 2016-12-07 Korea Advanced Institute Of Science And Technology Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US8343752B2 (en) 2011-05-03 2013-01-01 Verdezyne, Inc. Biological methods for preparing adipic acid
HRP20220455T1 (hr) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azid grupu
JP6421122B2 (ja) 2012-10-12 2018-11-07 ストロ バイオファーマ， インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
CA2909516C (en) 2013-04-19 2023-03-07 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
DK3041854T3 (da) 2013-08-08 2020-03-02 Scripps Research Inst En fremgangsmåde til stedspecifik enzymatisk mærkning af nukleinsyrer in vitro gennem inkorporering af unaturlige nukleotider
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
PL3055321T3 (pl) 2013-10-11 2019-02-28 Sutro Biopharma, Inc. SYNTETAZY tRNA DOŁĄCZAJĄCE AMINOKWAS NIENATURALNY DLA PARA-METYLOAZYDO-L-FENYLOALANINY
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015054590A2 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PYRIDYL TETRAZINE
CN104231068A (zh) 2014-01-27 2014-12-24 苏州发士达生物科技有限公司 人白细胞介素ii突变体及其应用
US10513706B2 (en) 2014-04-09 2019-12-24 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2016025385A1 (en) * 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3234170A4 (en) 2014-12-19 2018-07-25 Sutro Biopharma, Inc. Codon optimization for titer and fidelity improvement
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
MY188430A (en) 2015-04-10 2021-12-08 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
WO2017112825A2 (en) 2015-12-21 2017-06-29 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
KR102687530B1 (ko) * 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
HUE060123T2 (hu) 2016-06-24 2023-01-28 Scripps Research Inst Új nukleozid-trifoszfát-transzporter és alkalmazásai
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
WO2019131964A1 (ja) 2017-12-27 2019-07-04 協和発酵キリン株式会社 Ｉｌ－２改変体
US20200368293A1 (en) 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
CA3091857A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
CA3103603A1 (en) 2018-06-13 2019-12-19 Akron Biotechnology, LLC. Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions
MX2021000801A (es) 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020057646A1 (zh) 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20210113265A (ko) 2019-01-07 2021-09-15 인히브릭스, 인크. 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
AU2020252119B2 (en) 2019-03-29 2025-09-04 Centre National De La Recherche Scientifique - Cnrs Interleukin-2 variants with modified biological activity
KR20220004134A (ko) 2019-04-26 2022-01-11 프로린크스 엘엘시 서방형 사이토카인 컨쥬게이트
CA3143034A1 (en) 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
CA3148505A1 (en) 2019-08-12 2021-02-18 AskGene Pharma, Inc. Novel il-2 fusion molecules
AU2020328038B2 (en) 2019-08-13 2025-10-09 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP4013777A4 (en) 2019-08-15 2024-01-17 Cytimm Therapeutics, Inc. MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
CN114555128A (zh) 2019-08-15 2022-05-27 新索思股份有限公司 采用il-2缀合物的免疫肿瘤学组合疗法
CN114555632A (zh) 2019-08-23 2022-05-27 新索思股份有限公司 Il-15缀合物及其用途
CN114853874B (zh) 2019-09-10 2024-05-17 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
IL291786A (en) 2019-11-04 2022-06-01 Synthorx Inc Interleukin 10 conjugates and their use
AU2020401371A1 (en) 2019-12-13 2022-07-21 Synthekine, Inc. IL-2 orthologs and methods of use
KR20220118473A (ko) 2019-12-23 2022-08-25 신톡스, 인크. N6-((2-아지도에톡시)카르보닐)라이신의 제조 방법
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
JP2023531509A (ja) 2020-06-25 2023-07-24 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび抗ｅｇｆｒ抗体を用いる免疫腫瘍学併用療法
US20220016252A1 (en) 2020-06-25 2022-01-20 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
US12421286B2 (en) 2020-09-04 2025-09-23 Shandong Simcere Biopharmaceutical Co., Ltd. Il-2 mutant and application thereof
WO2022076859A1 (en) 2020-10-09 2022-04-14 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
AU2021356693A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2023137401A1 (en) 2022-01-13 2023-07-20 Synthorx, Inc. Methods for selecting subjects and treating cancer with il-2 therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250099355A1 (en) * 2023-07-18 2025-03-27 Sytheon Ltd Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity

Also Published As

Publication number Publication date
MA49767A (fr) 2021-05-26
AU2018309166B2 (en) 2022-12-08
IL272410B1 (en) 2025-08-01
US20250325632A1 (en) 2025-10-23
EP3661955A1 (en) 2020-06-10
US12377131B2 (en) 2025-08-05
IL272412A (en) 2020-03-31
NZ761434A (en) 2024-03-22
MX2024007634A (es) 2024-07-04
WO2019028425A1 (en) 2019-02-07
TW201920241A (zh) 2019-06-01
CO2020001823A2 (es) 2020-04-01
AU2023201482B2 (en) 2024-09-05
BR112020002272A2 (pt) 2020-07-28
KR20250130723A (ko) 2025-09-02
IL272412B1 (en) 2025-08-01
KR20240116580A (ko) 2024-07-29
IL272412B2 (en) 2025-12-01
JP2020529977A (ja) 2020-10-15
IL272410B2 (en) 2025-12-01
PH12020500241A1 (en) 2021-01-04
AU2018309172B2 (en) 2022-12-15
CA3071016A1 (en) 2019-02-07
MA49770A (fr) 2021-05-26
US20190314455A1 (en) 2019-10-17
AU2023200972A1 (en) 2023-03-23
AU2024278112A1 (en) 2025-01-02
AU2024278132A1 (en) 2025-01-02
NZ761430A (en) 2024-03-22
KR20250145137A (ko) 2025-10-13
AR112969A1 (es) 2020-01-15
JP2023082090A (ja) 2023-06-13
RU2020107926A3 (https=) 2021-12-27
EP3661956A1 (en) 2020-06-10
RU2020107917A (ru) 2021-09-03
MX2024007633A (es) 2024-07-04
US20200181220A1 (en) 2020-06-11
CO2020001828A2 (es) 2020-04-01
IL272410A (en) 2020-03-31
SG11202000939PA (en) 2020-02-27
SA520411202B1 (ar) 2024-03-05
US20230302089A1 (en) 2023-09-28
US20200188484A1 (en) 2020-06-18
SA520411204B1 (ar) 2024-07-01
RU2020107917A3 (https=) 2021-12-24
KR20200035102A (ko) 2020-04-01
AU2018309166A1 (en) 2020-02-27
TW202248207A (zh) 2022-12-16
CA3071013A1 (en) 2019-02-07
EP3661956A4 (en) 2021-04-28
IL322312A (en) 2025-09-01
KR102687649B1 (ko) 2024-07-26
US20250325633A1 (en) 2025-10-23
CN111183149A (zh) 2020-05-19
MX2020001332A (es) 2020-09-09
AU2023200972B2 (en) 2024-09-05
US12318431B2 (en) 2025-06-03
JP2024105594A (ja) 2024-08-06
KR20200035092A (ko) 2020-04-01
JP7654401B2 (ja) 2025-04-01
IL321812A (en) 2025-08-01
WO2019028419A1 (en) 2019-02-07
KR20240141853A (ko) 2024-09-27
US20200231644A1 (en) 2020-07-23
CN111194322A (zh) 2020-05-22
PH12020500238A1 (en) 2021-01-11
US11622993B2 (en) 2023-04-11
AU2023201482A1 (en) 2023-04-13
MX2020001336A (es) 2020-08-20
JP7258844B2 (ja) 2023-04-17
EP3661955A4 (en) 2021-05-26
JP2022169649A (ja) 2022-11-09
AU2018309172A1 (en) 2020-02-27
US11701407B2 (en) 2023-07-18
RU2020107926A (ru) 2021-09-03
US10610571B2 (en) 2020-04-07
US20240082359A1 (en) 2024-03-14
KR102708105B1 (ko) 2024-09-24
MY200827A (en) 2024-01-17
TWI906467B (zh) 2025-12-01
SG11202000944SA (en) 2020-02-27
TWI757528B (zh) 2022-03-11
JP2020529976A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
AU2023200972B2 (en) Cytokine conjugates for the treatment of proliferative and infectious diseases
US12521437B2 (en) IL-2 conjugates and methods of use thereof
RU2829327C2 (ru) Конъюгаты il-2 и способы их применения
RU2786116C2 (ru) Конъюгаты цитокинов для лечения пролиферативных и инфекционных заболеваний

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]